利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

87 条记录 (耗时 0.047 秒)

    HERNIA PATCH
    22.
    发明申请
    HERNIA PATCH 审中-公开
    赫尼亚·帕特

    公开(公告)号：US20110144667A1

    公开(公告)日：2011-06-16

    申请号：US12877919

    申请日：2010-09-08

    申请人： Anthony Richard Horton ,  Paul Martakos ,  Steve A. Herweck ,  Theodore Karwoski ,  Joseph F. Ferraro

    发明人： Anthony Richard Horton ,  Paul Martakos ,  Steve A. Herweck ,  Theodore Karwoski ,  Joseph F. Ferraro

    IPC分类号： A61B17/08

    CPC分类号： A61F2/0063 ,  A61F2210/0004 ,  A61F2210/0076 ,  A61F2220/0008 ,  A61F2220/0075 ,  A61F2230/0004 ,  A61F2250/0018 ,  A61F2310/00389 ,  A61K31/20 ,  A61L31/10 ,  A61L31/14 ,  A61L31/148

    摘要： A hernia patch supporting tissue in-growth conforms to a tissue wall upon surgical installation and fixation within a patient. The hernia patch can include a base and positioning straps. The base is formed of two layers that are affixed to each other around the perimeter of the patch, for example by stitching. A stabilizing washer is provided between the two layers, and the stitch is provided peripherally around the stabilizing washer, keeping the washer free-floating between the layers. The base, positioning straps, and stabilizing washer are formed of a structure that does not separate the layers of the implant or form a space in the form of a pocket, and promotes more uniform and confluent tissue incorporation or in-growth after implantation. The hernia patch may further include a hydrolysable bioabsorbable cross-linked coating of a fatty acid based material, such as an omega-3 fatty acid based material.

    摘要翻译： 支撑组织生长的疝补片在外科手术安装和固定在患者体内时符合组织壁。 疝补片可以包括基部和定位带。 底座由两层相互贴合，例如通过拼接而在贴片的周边彼此固定。 在两层之间设有一个稳定的垫圈，并且在周向围绕稳定垫圈设置线圈，保持垫片在层之间自由浮动。 基部，定位带和稳定垫圈由不分离植入物层或形成袋状空间的结构形成，并且在植入后促进更均匀和汇合的组织结合或生长。 疝补片可以进一步包括基于脂肪酸的材料如ω-3脂肪酸基材料的可水解生物可吸收的交联涂层。

    DRUG DELIVERY COATING FOR USE WITH A MEDICAL DEVICE AND METHODS OF TREATING VASCULAR INJURY
    23.
    发明申请
    DRUG DELIVERY COATING FOR USE WITH A MEDICAL DEVICE AND METHODS OF TREATING VASCULAR INJURY 审中-公开
    用于医疗设备的药物输送涂料和治疗血管损伤的方法

    公开(公告)号：US20100004738A1

    公开(公告)日：2010-01-07

    申请号：US11919315

    申请日：2006-04-28

    申请人： Steve A. Herweck ,  Paul Martakos ,  Geoffrey Moodie ,  Theodore Karwoski ,  Trevor Carlton

    发明人： Steve A. Herweck ,  Paul Martakos ,  Geoffrey Moodie ,  Theodore Karwoski ,  Trevor Carlton

    IPC分类号： A61F2/82 ,  A61F2/00 ,  A61K31/439 ,  A61M25/00 ,  A61B17/03

    CPC分类号： A61K31/436 ,  A61L27/54 ,  A61L29/16 ,  A61L31/16 ,  A61L2300/434 ,  A61L2300/45

    摘要： The present inventions provide various embodiments of methods for one or more of treating vascular injury, neointima proliferation and/or local inflammation in a mammal by locally administering therapeutic compound comprising a mTOR targeting compound and a calcineurin inhibitor. In various aspects, the therapeutic compound comprises a bio-absorbable carrier component carrier component at least partially formed of a cellular uptake inhibitor and a cellular uptake enhancer, a mTOR targeting compound and a calcineurin inhibitor. In various aspects, the present invention provides for controlled delivery, which is at least partially characterized by total and relative amounts of a cellular uptake inhibitor and cellular uptake enhancer in a bio-absorbable carrier component.

    摘要翻译： 本发明提供了通过局部施用包含mTOR靶向化合物和钙调磷酸酶抑制剂的治疗化合物来治疗哺乳动物血管损伤，新内膜增生和/或局部炎症中的一种或多种的方法的各种实施方案。 在各个方面，治疗化合物包括至少部分由细胞摄取抑制剂和细胞吸收增强剂，mTOR靶向化合物和钙调磷酸酶抑制剂形成的生物可吸收载体组分载体组分。 在各个方面，本发明提供受控递送，其至少部分地表征为生物可吸收载体组分中的细胞摄取抑制剂和细胞摄取增强剂的总量和相对量。

    Bio-absorbable oil suspension
    24.
    发明申请
    Bio-absorbable oil suspension 审中-公开
    生物吸收油悬浮液

    公开(公告)号：US20080207756A1

    公开(公告)日：2008-08-28

    申请号：US11711389

    申请日：2007-02-27

    申请人： Steve A. Herweck ,  Theodore Karwoski ,  Paul Martakos

    发明人： Steve A. Herweck ,  Theodore Karwoski ,  Paul Martakos

    IPC分类号： A61K31/20 ,  A61P39/00

    CPC分类号： A61K31/20

    摘要： Exemplary embodiments of the invention provide a dispersing liquid for coating internal body tissues with a bio-absorbable oil, a method of making the dispersing liquid, methods of using the dispersing liquid and a kit for coating internal body tissues using the dispersing liquid. The dispersing liquid includes a suspension of a bio-absorbable oil suspended in a liquid carrier. The invention results in a uniform thin coating of bio-absorbable oil on internal body tissues.

    摘要翻译： 本发明的示例性实施方案提供了用生物可吸收油涂覆内部身体组织的分散液，制备分散液的方法，使用分散液的方法和使用分散液涂覆内部身体组织的试剂盒。 分散液包括悬浮在液体载体中的生物可吸收油的悬浮液。 本发明导致生物吸收油在内部身体组织上的均匀薄涂层。

    Tissue separating device with reinforced support for anchoring mechanisms
    25.
    发明授权
    Tissue separating device with reinforced support for anchoring mechanisms 有权
    组织分离装置，具有用于锚固机构的加强支撑

    公开(公告)号：US09592324B2

    公开(公告)日：2017-03-14

    申请号：US11980155

    申请日：2007-10-30

    申请人： Steve A. Herweck ,  Joseph Ferraro ,  Paul Martakos ,  Theodore Karwoski ,  Anthony Richard Horton

    发明人： Steve A. Herweck ,  Joseph Ferraro ,  Paul Martakos ,  Theodore Karwoski ,  Anthony Richard Horton

    IPC分类号： A61L31/14 ,  A61L31/08

    CPC分类号： A61L31/14 ,  A61F2/0063 ,  A61L31/08

    摘要： A barrier layer device is formed of an underlying biocompatible structure having a barrier layer coating that can exhibit anti-inflammatory properties, non-inflammatory properties, and/or adhesion-limiting properties, as well as generate a modulated healing effect on injured tissue. As implemented herein, the barrier layer is a non-polymeric cross-linked gel derived at least in part from a fatty acid compound, and may include a therapeutic agent. The underlying structure can be in the form of a surgical mesh. The barrier device is further provided with reinforced sections or portions to aid with the fastening of the barrier device for implantation purposes and prohibits or substantially reduces the occurrence of excessive stretching and tearing. The barrier device is implantable in a patient for short term or long term applications, and can include controlled release of the therapeutic agent.

    摘要翻译： 阻挡层装置由潜在的生物相容性结构形成，该结构具有可显示抗炎性质，非炎症性质和/或粘附限制性质的阻隔层涂层，并且对损伤的组织产生调节的愈合作用。 如本文所实施的，阻挡层是至少部分地由脂肪酸化合物衍生的非聚合交联凝胶，并且可以包括治疗剂。 底层结构可以是手术网的形式。 阻挡装置还设置有加强部分或部分，以帮助阻挡装置紧固以用于植入目的，并且禁止或基本上减少过度拉伸和撕裂的发生。 阻挡装置可植入患者体内以进行短期或长期应用，并且可包括治疗剂的受控释放。

    Barrier layer with underlying medical device and one or more reinforcing support structures
    26.
    发明授权
    Barrier layer with underlying medical device and one or more reinforcing support structures 有权
    具有底层医疗装置和一个或多个加强支撑结构的阻隔层

    公开(公告)号：US09492596B2

    公开(公告)日：2016-11-15

    申请号：US11701799

    申请日：2007-02-02

    申请人： Steve A. Herweck ,  Joseph Ferraro ,  Paul Martakos ,  Theodore Karwoski ,  Anthony Richard Horton

    发明人： Steve A. Herweck ,  Joseph Ferraro ,  Paul Martakos ,  Theodore Karwoski ,  Anthony Richard Horton

    IPC分类号： A61F2/02 ,  A61L31/14 ,  A61L31/16

    CPC分类号： A61L31/145 ,  A61F2/0063 ,  A61F2/82 ,  A61F2002/0086 ,  A61F2002/009 ,  A61L31/16 ,  A61L2300/41 ,  A61L2300/606

    摘要： A barrier layer device is formed of an underlying biocompatible structure having a barrier layer coating that can exhibit anti-inflammatory properties, non-inflammatory properties, and/or adhesion-limiting properties, as well as generate a modulated healing effect on injured tissue. As implemented herein, the barrier layer is a non-polymeric cross-linked gel derived at least in part from a fatty acid compound, and may include a therapeutic agent. The underlying structure can be in the form of a surgical mesh. The barrier device is further provided with anchoring reinforcements to aid with the fastening of the barrier device for implantation purposes and reinforcing truss sections or portions that prohibit or substantially reduce the occurrence of excessive stretching and tearing. The barrier device is implantable in a patient for short term or long term applications, and can include controlled release of the therapeutic agent.

    摘要翻译： 阻挡层装置由潜在的生物相容性结构形成，该结构具有可显示抗炎性质，非炎症性质和/或粘附限制性质的阻隔层涂层，并且对损伤的组织产生调节的愈合作用。 如本文所实施的，阻挡层是至少部分地由脂肪酸化合物衍生的非聚合交联凝胶，并且可以包括治疗剂。 底层结构可以是手术网的形式。 隔离装置还设置有锚固加强件，以帮助阻挡装置的固定用于植入目的，并且加强桁架部分或部分，其禁止或基本上减少过度拉伸和撕裂的发生。 阻挡装置可植入患者体内以进行短期或长期应用，并且可包括治疗剂的受控释放。